MEN1 and cancer: At this time, due to the high clinical probability of MEN1, after further informed consent from the patient her leukocyte DNA was analyzed by next-generation sequencing (TruSight Cancer Sequencing panel, Illumina), and a novel heterozygous germline mutation in exon 9 of the MEN1 gene (c.1321_1323dup) was found, which is expected to lead to a duplication of the tryptophan residue (p.Trp441dup) of MENIN.